These results suggest that DAC+IA followed by HLA-mismatched allo-TLI improved response and survival rates in elderly AML patients, and can be an alternative therapy for “fit” elderly AML patients other than intensive chemotherapy or Bcl-2 inhibitor based therapies. This evidence concerns the gene BCL2 and acute myeloid leukemia.